Last reviewed · How we verify
NCT07347132
Comparison of Pathological Outcome and Recurrence Rate Between En Bloc and Conventional Transurethral Resection of Bladder Tumor
NA trial testing En Bloc Transurethral Resection of Bladder Tumor in Urinary Bladder Neoplasms in 116 participants. Completed in 30 November 2025.
30 November 2025
Quick facts
| Lead sponsor | Lahore General Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 116 |
| Start date | 1 September 2024 |
| Primary completion | 30 November 2025 |
| Estimated completion | 30 November 2025 |
| Sites | 1 location across Pakistan |
Drugs / interventions tested
- En Bloc Transurethral Resection of Bladder Tumor
- Conventional Transurethral Resection of Bladder Tumor
Conditions studied
- Urinary Bladder Neoplasms — all drugs for Urinary Bladder Neoplasms →
- Non-muscle Invasive Bladder Cancer — all drugs for Non-muscle Invasive Bladder Cancer →
Sponsor
Lahore General Hospital
Who can join
Adults 18 to 60, any sex, with Urinary Bladder Neoplasms or Non-muscle Invasive Bladder Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Bladder cancer that has not invaded the bladder muscle often returns after treatment, creating repeated procedures and ongoing anxiety for patients. The standard initial treatment is transurethral resection of bladder tumour (TURBT), in which visible tumours are removed through a telescope passed into the bladder. Conventional TURBT usually removes the tumour in multiple pieces, which may reduce specimen quality for laboratory assessment and may increase the chance that small tumour fragments remain or spread during removal. En bloc TURBT is a newer technique that aims to remove the tumour in one intact piece, which may improve the quality of the tissue specimen for accurate staging and grading, allow better assessment of surgical margins, and potentially reduce recurrence. This randomized controlled trial was conducted in the Department of Urology, Lahore General Hospital and PGMI, Lahore. A total of 116 adults (18 to 60 years) with non-muscle invasive bladder cancer were enrolled and randomly assigned to en bloc TURBT or conventional TURBT (58 patients per group). Resected specimens were evaluated by pathologists who was not be informed of the surgical technique. The study was compare key pathological outcomes, including the presence of detrusor muscle in the specimen, histological grade, tumour stage accuracy, specimen integrity, and the ability to assess lateral and deep resection margins. Participants were followed for 15 months, with surveillance at 3-month intervals.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07347132
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Urinary Bladder Neoplasms
Currently open trials in the same condition.
- NCT07222488 — A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003) · Phase 1, PHASE2 · recruiting
- NCT06421142 — FAPI and FDG PET/MRI in Diagnosis and Therapy Prediction of Bladder Cancer · NA · active not recruiting
- NCT04369560 — Virtual Histology of the Bladder Wall for Bladder Cancer Staging · EARLY_PHASE1 · recruiting
- NCT06960577 — Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cance · Phase 3 · recruiting
- NCT06833073 — A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011) · Phase 2 · recruiting
Other Lahore General Hospital trials
Trials by the same sponsor.
- NCT07470359 — Comparison of Functional Outcomes Following Arthroscopic ACL Reconstruction With Peroneus Longus Autograft With and With · Phase 2 · recruiting
- NCT07261306 — Comparison Between Oral Methotrexate and Tofacitinib in Chronic Plaque Psoriasis · EARLY_PHASE1 · recruiting
- NCT07112898 — Effect of Platelet-Rich Plasma on Graft Uptake and Postoperative Outcomes in Full-Thickness Skin Grafting of Face and Ne · NA · enrolling by invitation
- NCT07478874 — Prophylaxis Against Surgical Site Infections Using Local as Well as Systemic Antibiotic · NA · completed
- NCT07460908 — Comparison of Terlipressin Versus Octreotide in Patients With Hepatorenal Syndrome · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07347132 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Lahore General Hospital
- Last refreshed: 16 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07347132.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing